These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16785120)

  • 1. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
    Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 3. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current use of imatinib in the treatment of chronic myeloid leukemia.
    O'Dwyer M
    Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib therapy in chronic myeloid leukemia.
    Crossman LC; O'Brien SG
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):605-17, viii. PubMed ID: 15271395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of imatinib in the treatment of acute lymphoid leukemias].
    Poros A; Lovas N
    Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
    Champlin RE; Kantarjian H
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
    Chen F; Li L; Ma D; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2010 Feb; 34(2):e75-7. PubMed ID: 19773083
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 10. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
    Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
    Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 13. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
    Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
    Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual disease in chronic myeloid leukemia after induction of molecular remission.
    Lange T; Niederwieser DW; Deininger MW
    N Engl J Med; 2003 Oct; 349(15):1483-4. PubMed ID: 14534349
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic myeloid leukemia].
    Hochhaus A
    Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
    [No Abstract]   [Full Text] [Related]  

  • 17. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S; Yano K; Kobayashi M
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
    Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
    Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
    Yagasaki F
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.